Immunic (IMUX) Cash from Investing Activities (2013 - 2026)
Immunic's (IMUX) quarterly Cash from Investing Activities came in at -$2000.0 in Q1 2026, up 95.74% year-on-year from -$1021.7 in Q1 2025, and up 81.82% quarter-over-quarter from -$11000.0 in Q4 2025.
Immunic (IMUX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Immunic has disclosed Cash from Investing Activities across 14 years of filings, most recently posting -$2000.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$2000.0, up 95.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$116000.0 (up 58.57% YoY), and the FY2025 annual result was -$161000.0, up 39.02% from the prior year.
- Cash from Investing Activities came in at -$2000.0 for Q1 2026 at Immunic, up from -$11000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $5.3 million in Q1 2023 to a low of -$9.6 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$36000.0 (2025), against an average of -$41529.4.
- Across the five-year window, Cash from Investing Activities tumbled 50573.68% in 2022 and jumped 44558.33% in 2023, its largest moves.
- Immunic's Cash from Investing Activities stood at -$9.6 million in 2022, then jumped by 98.29% to -$165000.0 in 2023, then soared by 98.18% to -$3000.0 in 2024, then plunged by 266.67% to -$11000.0 in 2025, then surged by 81.82% to -$2000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$2000.0 (Q1 2026), -$11000.0 (Q4 2025), and -$67000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 579,519.10 |
| 10 | Immunic | 384.84 Mn | 198.21 Mn | - | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | -67,000.00 |
| Sep 30, 2025 | -67,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Dec 31, 2023 | -165,000.00 |